6.15 0.00 (0.00%)
After hours: 5:25PM EST
|Bid||6.14 x 3100|
|Ask||6.30 x 1400|
|Day's Range||6.03 - 6.30|
|52 Week Range||2.80 - 6.45|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.17|
Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
Picking breakout stocks is one of the most-favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.
BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 5.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BELBUCA® Net Sales Increased by 115% versus Prior Year to All-time High of $26.5 Million Raises Full Year 2019 Total Company Net Sales Expectations to $105 - $110 Million.
RALEIGH, N.C., Nov. 07, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Unifi, BioDelivery Sciences International, Crocs, Anika Therapeutics and Plexus
Zacks.com featured highlights include: Universal Forest Products, BioDelivery Sciences International, CBIZ, Euronav and The Bancorp
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Possibility of at least an interim trade deal between the largest trading countries of the world boosted investors' confidence on risky assets like equities.
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
RALEIGH, N.C., Oct. 30, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic.
BioDelivery Sciences International, Inc. (BDSI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Once again, top executives with ties to Triangle companies are walking away with millions of dollars in insider stock sales.
Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred.
RALEIGH, N.C., Sept. 17, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
RALEIGH, N.C., Aug. 29, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.